Physician
Hematology
Dr. Scott I. Bearman, MD
|
|
Give Review
Scott I. Bearman practices Hematology. He researched medicine at Tufts University School of Medicine. Tufts University School of Medicine has a rank of 49 in research and a 52 in primary care Scott Bearman is a published doctor. He has 89 publications published. The most current publication "Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy." Scott Bearman accepts Medicare payments and is registered with Medicare.gov.
Publications
- Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total...
- Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy.
- Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advance...
- Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
- Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor c...
- Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy.
- Reduced-intensity allogeneic stem cell transplantation.
- Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response withou...
- Renal dysfunction in allogeneic hematopoietic cell transplantation.
- Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.
- Transplantation of ex vivo expanded cord blood.
- American Society for Blood and Marrow Transplantation guidelines for clinical centers.
- Chronic graft-versus-host disease and other late complications of bone marrow transplantation.
- Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer.
- High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors.
- High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
- Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
- Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-gra...
- Peripheral blood stem cell harvesting and CD34-positive cell selection.
- Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients.
- Peripheral blood stem cells for autografting.
- Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.
- High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.
- Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation.
- Use of amifostine in bone marrow purging.
- Bone marrow metastases.
- High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.
- High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer.
- Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver.
- Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
- Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer.
- Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.
- Role of autotransplantation in treatment of other solid tumors.
- A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation.
- Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy wit...
- Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support.
- Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors.
- [Veno-occlusive disease of the liver after bone marrow transplantation. Report of the symposium Autograft in France and the group of study of bone marrow transplantati...
- The syndrome of hepatic veno-occlusive disease after marrow transplantation.
- New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
- Transplantation of CD34+ hematopoietic progenitor cells.
- Positive selection of CD34+ hematopoietic progenitor cells for transplantation.
- Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood p...
- Incorporation of glucosamine by activated human neutrophils. A myeloperoxidase-mediated process.
- The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation.
- Intracellular localization of lactosylceramide, the major human neutrophil glycosphingolipid.
- Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with...
- Regimen-related toxicity in patients undergoing bone marrow transplantation.
- Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignan...
- Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma.
- A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation.
- Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity.
- Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.
- Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.
- Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens.
- Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.
- Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
- Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.
- Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant.
- Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation.
- Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell.
- Effects of oxygen tension and pH on the respiratory burst of human neutrophils.
- Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
- Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
- Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.
- Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest...
- Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
- High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
- High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
- Stem cell isolation.
- Use of stem cell factor to mobilize hematopoietic progenitors.
- Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft.
- Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
- Avoiding hepatic veno-occlusive disease: what do we know and where are we going?
- Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia.
- Status of high-dose chemotherapy for breast cancer: a review.
- Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer.
- Peripheral blood stem cell transplantation in breast cancer.
- High-dose chemotherapy for breast cancer.
- Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation.
- High-dose chemotherapy for breast cancer: we have not heard the final word.
- Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.
- Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and au...
- Veno-occlusive disease of the liver.
- A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
- Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support.
- Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
- Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility...
Schools
Tufts University School Of Medicine
University Washington Affil Hospital
University Of Washington Medical Center
Hutchinson Cancer Research Center University
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Washington -
Tufts University School of Medicine
Drug Facts
| NPI NUMBER | 1528042249 | |
| NPPES Provider LastName | BEARMAN | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 802181238 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 683.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 43.0 | |
| Percent Opioid Claims | 6.3 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528042249 |
| Last Name Of The Provider | BEARMAN |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
Dr. John A. van Doorninck, MD |
|
Dr. Robert L. Garcea, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Cynthia M. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Raich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellina K. Hall, DO |
|
Dr. Thomas J. Kenney III, MD |
|
|
Dr. John L. Shaia, MD |
|
Dr. Alan S. Feiner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Freeman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Peter A. McSweeney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher L. Gonzalez, MD |